JP2023501617A5 - - Google Patents

Info

Publication number
JP2023501617A5
JP2023501617A5 JP2022527817A JP2022527817A JP2023501617A5 JP 2023501617 A5 JP2023501617 A5 JP 2023501617A5 JP 2022527817 A JP2022527817 A JP 2022527817A JP 2022527817 A JP2022527817 A JP 2022527817A JP 2023501617 A5 JP2023501617 A5 JP 2023501617A5
Authority
JP
Japan
Prior art keywords
cells
population
cell
gene
grna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022527817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/060722 external-priority patent/WO2021095012A1/en
Publication of JP2023501617A publication Critical patent/JP2023501617A/ja
Publication of JP2023501617A5 publication Critical patent/JP2023501617A5/ja
Pending legal-status Critical Current

Links

JP2022527817A 2019-11-13 2020-11-13 Car-t細胞を製造する方法 Pending JP2023501617A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934999P 2019-11-13 2019-11-13
US62/934,999 2019-11-13
PCT/IB2020/060722 WO2021095012A1 (en) 2019-11-13 2020-11-13 Methods of manufacturing car-t cells

Publications (2)

Publication Number Publication Date
JP2023501617A JP2023501617A (ja) 2023-01-18
JP2023501617A5 true JP2023501617A5 (https=) 2023-11-06

Family

ID=75845429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527817A Pending JP2023501617A (ja) 2019-11-13 2020-11-13 Car-t細胞を製造する方法

Country Status (14)

Country Link
US (1) US20210139935A1 (https=)
EP (1) EP4058559A1 (https=)
JP (1) JP2023501617A (https=)
KR (1) KR20220097985A (https=)
CN (1) CN114901808A (https=)
AR (1) AR120470A1 (https=)
AU (1) AU2020382017A1 (https=)
BR (1) BR112022009137A2 (https=)
CA (1) CA3158118A1 (https=)
CO (1) CO2022006800A2 (https=)
IL (1) IL292351A (https=)
MX (1) MX2022005817A (https=)
TW (1) TW202132560A (https=)
WO (1) WO2021095012A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202328444A (zh) * 2021-07-26 2023-07-16 瑞士商Crispr治療公司 用於製造基因工程化car-t細胞之方法
CN116023496B (zh) * 2021-10-27 2026-02-27 菲鹏弘济生物(深圳)有限公司 一种制备通用型car-t细胞的方法及其应用
AU2023314130A1 (en) * 2022-07-25 2025-02-06 Memorial Hospital For Cancer And Allied Diseases Manufacturing processes for adoptive cell therapies
AU2023373900A1 (en) * 2022-11-02 2025-05-15 Medisix Therapeutics, Inc. Methods and systems for production of engineered t-cells
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
AU2013266968B2 (en) * 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
CN113355357B (zh) * 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
GB201418965D0 (https=) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CN107250373A (zh) * 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
EP4628587A3 (en) * 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
US20190136230A1 (en) * 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
DE102016211884A1 (de) 2016-06-30 2018-01-04 Zf Friedrichshafen Ag Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
WO2018157072A1 (en) * 2017-02-27 2018-08-30 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
CN107392652A (zh) 2017-06-30 2017-11-24 广州市中崎商业机器股份有限公司 基于收银纸背面进行针对性广告发布的系统及方法
AU2018313167A1 (en) * 2017-08-08 2020-02-27 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
CN108192927A (zh) * 2017-12-29 2018-06-22 上海海洋大学 一种瓯江彩鲤的基因编辑与过表达操作方法
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
BR112020016176A2 (pt) * 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.

Similar Documents

Publication Publication Date Title
JP2023501617A5 (https=)
JP2023501580A5 (https=)
JP7654702B2 (ja) キメラ抗原受容体及び他の受容体の発現に対するt細胞
US20250002850A1 (en) Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
AU2018202976B2 (en) Polyclonal gamma delta t cells for immunotherapy
JP7190096B2 (ja) 遺伝子編集t細胞及びその使用
CN115175695A (zh) 制备表达嵌合抗原受体的细胞的方法
TW202030323A (zh) 製備表現嵌合抗原受體的細胞之方法
TW201903145A (zh) 將基因編輯用於產生通用型t細胞受體重導向的t細胞以進行輸入免疫治療的用途
BR112020007710A2 (pt) métodos para produzir células que expressam receptor de antígeno quimérico
CN107249606A (zh) 改变修饰的t细胞中的基因表达及其用途
CN114929862A (zh) 用于制备表达嵌合抗原受体的t细胞的生产方法
WO2024140778A1 (zh) Nkg2d工程化细胞及其组合物
KR20240007204A (ko) 키메라 항원 수용체 및 이를 포함하는 변형된 세포
JP2024525609A5 (https=)
JP2025066794A (ja) 遺伝子改変自己t細胞を製造するためのプロセス
Yu et al. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method
US20230054266A1 (en) Method for purifying ucart cell and use thereof
CN115835873A (zh) 用于产生表达重组受体的供体分批细胞的方法
CN116622712A (zh) 用于敲除t细胞中的trac和b2m的试剂和方法
CN109563484A (zh) 用于细胞活化的方法和试剂盒
WO2024193714A1 (zh) 细胞免疫疗法的组合物和方法
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
US20220145252A1 (en) Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2025040046A1 (zh) 体内半衰期延长的工程化t细胞及其制备方法